Stephanie Dudzinski MD, PhD

Over the moon that @sumeethj and I have matched at @MDAndersonNews and @BCMNeurosurgery for #radonc and #neurosurgery! We can't wait to start this new chapter of our lives with our family and incredible co-residents! #HoustonBound #Match2021

💡 New Role: **Curie Lead** – ACRO Resident Committee Liaise with Curie Journal to connect residents with research & involvement opportunities. Due: June 5th, 2026 acro.org/page/residentC… #RadOnc #Research

✅ ACRO Resident Committee Eligibility: • Current RadOnc resident (US or Canada) • Willing to commit 2 years • Not on exec committee of other RadOnc resident groups Deadline: June 5th, 2026 Apply now: acro.org/page/residentC… #RadOnc #ResidentLeadership

A culmination of decades of work defining the role of protons for locally-advanced NSCLC. @liao_zhongxing's @UTMDAnderson long-term randomized outcomes of proton therapy for locally-advanced NSCLC just published in @ASTRO_org @IJROBP. redjournal.org/article/S0360-…

🚨The first American guidelines for low-dose radiotherapy in osteoarthritis were just published. That’s not a small thing. For decades, European centers have been treating OA with low-dose RT. American patients largely couldn’t access it. No formal guidance. No insurer framework. No roadmap for referring providers. That changes today. The American Radium Society Appropriate Use Criteria, published in the American Journal of Clinical Oncology, define exactly when and how to use LDRT for OA. Radiation oncologists, rheumatologists, physiatrists, and orthopedic surgeons built this together. For insurers, this is the clinical framework they’ve been waiting for. Honored to be a co-author alongside the global experts who made this possible.

Don’t miss special coverage of @NRGonc research at #ASCO2026 on the NRG Oncology Podcast w @lauren_henke @APDicker @rne_md & Krishnan Patel. @ASCO @NCICancerTrials @ASTRO_org

Ab#5082 @ASCO #ASCO26 by @Soum_Roy_RadOnc👉bit.ly/4wKOPPj👉Baseline NADIR model predicts 6-mo PSA👉independently validated in Ph3 ARCHES in pts w/ enza-treated mHSPC #prostatecancer👇@DrSpratticus @oncoalert @urotoday @PCF_science @OpenMedicineHQ

Huge congrats to my friend and mentor @ACKoongMDPhD. Couldn’t be a better person for this role!

I am excited to join the @MayoClinic @MayoRadOnc team in Florida as Mayo expands its next-generation #radonc program. @DanTrifMD @KarinaNietoMD @BradfordHoppe @albertattia7 @LauraVallow @fantinegiap et al x.com/MayoClinic/sta…

🎙️NEW Special Episode of On Target: "Meet the Medical Physicist: Imaging and Radiation Therapy" Jointly sponsored by ASTRO and AAPM, this special episode of On Target features a conversation with medical physicists and physicians from radiology and radiation oncology, hosted by medical physicist Julianne Pollard-Larkin, PhD. Listen on: ASTRO's website: ow.ly/oomM50Z2q7B Spotify: ow.ly/M6Zf50Z2q7E Apple Podcasts: ow.ly/uXmG50Z2q7F @aapmHQ @JulieLarkin305

Everytime I read FASTRACK I/II results I end feeling like we should be using SBRT for primary RCC much more, especially in older patients. Still, by using RECIST to define their local failure (≥20% size increase), they need a big change to achieve that definition +1 cm for a 5 cm mass. That growth takes some time even in untreated RCC. Distant control seems important here- and the freedom-from-metastasis curve looks really good. Would love to see that curve subsetted to their bigger masses (≥5cm or ≥4 cm). T1a (35% of cohort) unlikely to metastasize even with observation. Not sure if the T1b subset has ever been presented separately?

I am humbled and honored to serve our research community that is committed to making advancements in #cancer prevention, detection, treatment, and survivorship. I look forward to advancing our mission to #endcancer by building upon our core strength in translational research.

I am not loving this trend of AI generated infographic explanation of pivotal clinical trial data. Many of them are straight up wrong as they aren’t peer reviewed or even created by an expert in that cancer type. Be CAREFUL when using these to learn about data and look at the source. #bcsm #breastcancer

Is SBRT (36.25 Gy/5#) non-inferior to MHRT in high-risk & N+ prostate cancer? 526 patients, 3 centres, mpMRI + PSMA staging, 77% whole-pelvis RT. Largest RCT in this population. From @TataMemorial @RadOncTMC 🔥 #ESTRO2026

Tune into @NRGonc Podcast next week for #ASCO2026 high impact studies hot off press w @rne_md, Krishnan Patel & @APDicker. @lauren_henke @felixfengmd @MaryFengMD @UTMDAnderson @KimmelCancerCtr @RTOGFoundation @GOG @DrPaulNguyen @UCSDCancer

Amazing thread

Let’s talk about prostate and urethra contouring on MRI. Three recent 📄📄📄 @SeibertLab #radonc #ProstateCancer 🧵1️⃣ @IJROBP @RO_GreenJournal @ARRO_org @ASTRO_org @ESTRO_org

Indeed, @ESTRO_RT, @ASTRO_org & our sister Urology societies have & will engage in productive, data-driven discussions to increase pt awareness & optimize pt outcomes. More to come…. Debates & competition are healthy - so long as we don’t lose sight of whose best interest we’re serving.

1/ A very real problem in modern radiation oncology: The treatment plan is often highly detailed. The hospital record is often not. The TPS knows exactly what we treated, where we treated it, and to what dose. But much of that context never leaves the bunker. #ESTRO26 #RadOnc

Excited to share that I recently attended #ESTRO 2026, where I was a presenter. Had a great time advancing innovation, research and patient care.

One of the standout talks of #ESTRO2026 👏 'A lot to be proud of' @alison_tree brilliantly highlighted how modern #RadOnc in #PCa is evolving beyond technology alone , with increasing focus on continenze, sexual function and QoL alongside outstanding cancer control!